COMBINATION OF REFAMETINIB AND CETUXIMAB IN METASTATIC COLORECTAL CANCER TO PREVENT RESISTANCE.

ABSTRACT: Primary objectives: ARES trial seeks to establish whether a double blockade of the EGFR/MAPK pathway, achievable by combining cetuximab with the MEK inhibitor refametinib, could prevent or treat EGFR-directed secondary resistance in metastatic colorectal cancer. for ARES 0: Define the RP2D of refametinib + CET for ARES 1: Shift 35% of the SD patients in the OR category.for ARES 2: Increase Disease Control rate from 15% to 40% Primary endpoints: for ARES 0: DLTs cycle 1 TRAEs by NCI-CTCAE v 4.0for ARES 1: Tumor response by RECIST v1.1for ARES 2: Disease control by RECIST v1.1

DISEASE(S): Colorectal Neoplasms Malignant,Metastatic Colorectal Carcinoma (mcrc),Carcinoma Metastatico Del Colon-retto

PROVIDER: 2533411 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR